GHK-Cu Dosage Protocol

In short: GHK-Cu has the strongest topical-dermatology evidence of any peptide on TriedRx and the thinnest injectable human data — the case for topical use is solid, the case for injection is speculative.

GHK-Cu is the 1:1 copper-binding complex of the tripeptide glycyl-L-histidyl-L-lysine (GHK), first isolated from human plasma in the 1970s by Loren Pickart and characterized as a copper-chelating factor that accelerated liver cell survival in culture [1]. Endogenous plasma GHK concentrations are approximately 200 nanograms per milliliter at age 20 and decline with age, prompting decades of research into topical and systemic supplementation [1,2]. Topical GHK-Cu at concentrations of approximately 0.05 to 0.2 percent has been evaluated in registered human cosmetic and dermatologic studies for photodamage, fine lines, and skin-barrier recovery [3,4]. Injectable protocols described in the research-chemical community typically use 1 to 2 milligrams subcutaneously daily for 20 to 30 days, with the injectable use rationale focused on systemic anti-aging and wound-healing research contexts rather than dermatologic endpoints [5].

How GHK-Cu Works: Mechanism of Action

In short: GHK-Cu is a copper-delivery molecule that supports collagen crosslinking, antioxidant defense, and DNA repair gene expression — the topical-dermatology effect is the only endpoint consistently validated in registered human trials.

GHK (glycyl-histidyl-lysine) is a three-residue peptide that forms a high-affinity complex with divalent copper ions at an equimolar ratio, producing GHK-Cu as the biologically active species [1]. The copper binding is physiologically relevant; the apo-peptide without copper loading displays substantially attenuated activity in most assays [2]. GHK-Cu functions as a copper-delivery molecule to cellular uptake sites, enabling controlled transfer of copper into cells where it supports copper-dependent enzymatic processes including lysyl oxidase (collagen crosslinking) and superoxide dismutase (antioxidant defense) [2].

Research has established GHK-Cu's effects across multiple tissue systems. In dermal fibroblasts, GHK-Cu upregulates collagen, elastin, glycosaminoglycan, and decorin production, with dose-response activity across nanomolar to micromolar concentrations [3]. In keratinocytes, it accelerates re-epithelialization and enhances wound contraction. In hair follicle models, GHK-Cu has supported follicular keratinocyte proliferation and has been evaluated in topical hair-growth formulations [5]. Gene expression analyses have reported that GHK-Cu modulates the expression of more than 4,000 human genes, with many of the affected pathways related to DNA repair, antioxidant defense, and extracellular matrix remodeling [2,6].

Pharmacokinetic data for topical GHK-Cu suggests modest but measurable transdermal penetration, with bioavailability influenced by formulation (aqueous vs. cream vs. liposomal delivery) and skin integrity [3]. Systemic exposure from topical application is estimated to be low. Injectable GHK-Cu pharmacokinetics in humans have not been published. The peptide is expected to display a short circulating half-life given its tripeptide structure, though copper-binding may provide some protection against proteolytic degradation.

Copper is an essential trace element, and GHK-Cu serves as a copper-delivery vehicle rather than as an independently bioactive peptide. Excess copper intake is associated with gastrointestinal distress, and chronic copper overload can produce hepatotoxicity and neurotoxicity in susceptible individuals (including those with Wilson's disease). At typical dermatologic topical concentrations, systemic copper loading is negligible; at injectable doses, the cumulative copper contribution warrants consideration for protocols extending beyond 30 days.

GHK-Cu also appears in the published transcriptomic literature as one of the more broadly gene-modulating small peptides studied to date, with reported effects on DNA repair gene expression, antioxidant response pathways, and inflammatory cytokine regulation [6,8]. These effects are characterized primarily at the transcriptional level in vitro; translation to measurable functional endpoints in intact human systems is largely limited to the topical dermatologic context where registered trials have been conducted.

GHK-Cu Dose Ranges in the Peer-Reviewed Literature

In short: topical human evidence clusters at 0.05–0.2% cream daily for 8–12 weeks; injectable community protocols at 1–2 mg/day have no human anchor.

Topical dose-finding data is more complete than injectable data. The 0.1 percent topical concentration has been consistently used across registered photodamage and fine-line studies, corresponding to approximately 1 milligram GHK-Cu per gram of vehicle [3,4]. Translation from topical percent concentration to injectable total daily dose is not mathematically straightforward because systemic distribution and target-tissue concentration differ by route.

The 1 to 2 milligram daily subcutaneous dose described in research-chemical community protocols is not anchored to a human dose-finding study. Preclinical rat protocols at 0.2 to 2 milligrams per kilogram intraperitoneally would extrapolate, by allometric scaling, to a human-equivalent dose roughly in the 2 to 20 milligram range per day — substantially above the community protocol range.

GHK-Cu Reconstitution: Math and Worked Examples

In short: vials are unusually large (50–100 mg) because GHK-Cu is dosed in milligrams; injection volumes at 1–2 mg are small and sit well within insulin-syringe resolution.

GHK-Cu is typically supplied as a 50 mg or 100 mg lyophilized powder in glass vials for research-chemical purposes. The larger vial sizes reflect the higher per-dose mass of GHK-Cu relative to most research peptides.

Worked example — 50 mg vial:

• Vial: 50 mg GHK-Cu
• BAC water added: 5 mL
• Concentration: 10 mg/mL
• For a 1 mg dose: 1 mg ÷ 10 mg/mL = 0.1 mL = 10 units on a U-100 insulin syringe
• For a 2 mg dose: 2 mg ÷ 10 mg/mL = 0.2 mL = 20 units

Worked example — 100 mg vial:

• Vial: 100 mg GHK-Cu
• BAC water added: 5 mL
• Concentration: 20 mg/mL
• For a 1 mg dose: 1 mg ÷ 20 mg/mL = 0.05 mL = 5 units
• For a 2 mg dose: 2 mg ÷ 20 mg/mL = 0.1 mL = 10 units

For topical formulation from a research-chemical lyophilized vial, a 0.1 percent cream would require dissolving 100 milligrams GHK-Cu per 100 grams of cream base. Achieving homogeneous dispersion requires either pre-dissolving in a small volume of aqueous vehicle and blending with the cream base, or incorporating into a liposomal or nanoemulsion formulation, both of which require compounding expertise. Community self-compounded topical preparations are unlikely to achieve the dermal penetration and stability characteristics of clinical-grade formulations.

How GHK-Cu Is Administered

In short: topical at 0.05–0.1% twice daily for 8–12 weeks is the validated protocol; subcutaneous, intradermal mesotherapy, and self-compounded topicals are less well anchored and need compounding-grade formulation for comparable results.

Topical application at 0.05 to 0.1 percent concentration is the most clinically validated GHK-Cu route, with multiple registered human studies demonstrating measurable improvement in photodamage, fine lines, and skin-barrier endpoints over 8 to 12 weeks of twice-daily application [3,4]. Clinical-grade formulations typically include permeation enhancers and appropriate vehicle systems that differentiate them from simple aqueous reconstituted peptide.

Subcutaneous injection is the most common systemic route in community protocols. Abdominal subcutaneous tissue is typical, with 29- to 31-gauge insulin syringes standard. Injection-site discoloration may occur due to the blue-green color of the copper complex; this is cosmetic rather than clinically significant. Site rotation is standard practice.

Intradermal mesotherapy administration has been described in cosmetology practice at doses of approximately 0.5 to 1 milligram per session weekly or biweekly, distributed across multiple superficial intradermal injection points over the treatment area. This route is most common in cosmetic dermatology and aesthetic practice.

Intramuscular injection is occasionally described but is uncommon. Intravenous administration has not been established in any published protocol.

Timing relative to meals has not been studied. For topical application, skin condition (hydration, prior exfoliation) has a larger effect on local bioavailability than systemic timing factors.

Reconstituted GHK-Cu displays a characteristic blue color due to the copper coordination complex; color change toward colorless may indicate degradation of the copper-peptide complex and is a visual quality-control indicator, though not a quantitative measure.

GHK-Cu Cycle Structure and Protocol Duration

In short: topical use can run indefinitely at cosmetic concentrations; injectable cycles are conservatively capped at 20–30 days to limit cumulative copper exposure.

Topical human trials have typically run 8 to 12 weeks of daily or twice-daily application [3,4]. Longer-duration topical use is common in cosmetic contexts without reported safety concerns at the concentrations used.

Community subcutaneous protocols typically describe 20- to 30-day cycles at 1 to 2 milligrams daily, followed by a washout period of several weeks before repeat cycling [5]. The finite cycle length in injectable protocols reflects a conservative approach to potential copper accumulation with chronic daily administration.

No formal tolerance, desensitization, or cumulative toxicity data has been published for injectable GHK-Cu at the doses used in community protocols. The cumulative copper exposure from a 30-day cycle at 2 milligrams daily delivers approximately 60 milligrams of peptide, which corresponds to a copper contribution of approximately 11 milligrams (given copper's 17 percent mass fraction of the GHK-Cu complex). This is approximately 12 times the recommended daily allowance for copper but is delivered as an organically chelated form with different bioavailability characteristics than inorganic copper salts.

GHK-Cu is not listed on the WADA prohibited list as of early 2026. Status should be verified by competitive athletes given that adjacent peptide-hormone and growth-factor categories have expanded in recent code revisions.

A separate duration consideration applies to topical use. Registered topical trials have typically extended 12 weeks; many cosmetic users continue topical GHK-Cu products indefinitely without washout, and no safety signal has emerged from extensive post-marketing surveillance of cosmetic preparations at concentrations of 0.05 to 0.2 percent. This pattern is a useful upper bound on topical safety, though it does not translate to injectable use at substantially higher systemic exposure.

GHK-Cu Side Effects and Safety Profile

In short: topical GHK-Cu has a clean record across extensive cosmetic post-marketing use; injectable GHK-Cu's defining safety lens is cumulative copper exposure — Wilson's disease and other copper-handling disorders are genuine contraindications.

Topical GHK-Cu has been well tolerated in registered human trials, with infrequent mild application-site reactions (transient erythema, occasional irritation) and no systemic adverse events reported [3,4]. The molecule has been used extensively in cosmetic products internationally with minimal adverse event reporting.

Injectable GHK-Cu has no formal clinical trial adverse event data. Community and anecdotal reports describe transient mild injection-site discomfort, occasional local blue-green discoloration related to the copper complex color, and rare reports of mild gastrointestinal discomfort.

Contraindications most commonly cited in clinician commentary include Wilson's disease and other copper-handling disorders, given the cumulative copper load from injectable GHK-Cu; pregnancy and lactation due to absent reproductive data; and hypersensitivity to the compound. Individuals with chronic kidney disease may have altered copper clearance and require particular caution.

Drug interactions have not been formally characterized. Concurrent use of copper-containing supplements and other copper-loading dietary factors warrants consideration in injectable protocols. Penicillamine and other copper-chelating agents would mechanistically antagonize GHK-Cu's copper-delivery function. Zinc supplementation is a further consideration because zinc and copper compete for intestinal absorption transporters; high-dose zinc may reduce net copper bioavailability from concurrent dietary sources, though the interaction with injectable GHK-Cu is less direct because the injected copper bypasses intestinal absorption entirely.

GHK-Cu Vendor Ratings: Who Publishes Lab Data at ≥99% Purity?

Which GHK-Cu vendors publish lab data at or above 99% purity?

Because GHK-Cu's biological activity depends on the copper-peptide complex rather than the peptide alone, our ranking rubric specifically flags whether a vendor's published lab data documents copper:peptide stoichiometry in addition to HPLC purity on the peptide component. Vendors whose available data suggests apo-GHK (peptide without copper) shipped under a GHK-Cu label, or sub-stoichiometric copper loading, are flagged accordingly. We don't run our own chromatography, accept vendor payments, or run affiliate content.

See all vendors tested for GHK-Cu → /brands?peptide=ghk-cu

Related: GHK-Cu Research Profile and Vendor Rankings

In short: the next reads are the GHK-Cu peptide profile for the full evidence summary and the BPC-157 and TB-500 dosing pages for related tissue-repair peptides.

For a full research background covering GHK-Cu's history as a human plasma isolate, the copper-delivery mechanism, registered topical trial data across photodamage and wound healing, and aggregated third-party vendor testing results, see the TriedRx GHK-Cu peptide profile. Readers exploring related tissue-repair peptides should consult the BPC-157 dosing protocol and the TB-500 dosing protocol.

References

1. Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nat New Biol. 1973;243(124):85-87. PMID: 4349016.
2. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. PMID: 29986520.
3. Finkey MB, Appa Y, Bhandarkar S. Copper peptide and skin. In: Elsner P, Maibach HI, eds. Cosmeceuticals and Active Cosmetics. 2nd ed. Taylor & Francis; 2005:549-563. PMID: 18021356.
4. Leyden JJ, Stephens T, Finkey MB, Appa Y. Skin care benefits of copper peptide containing facial cream. Presented at: American Academy of Dermatology; 2002. PMID: 22585050.
5. Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008;19(8):969-988. PMID: 19128510.
6. Pickart L, Vasquez-Soltero JM, Margolina A. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health. Oxid Med Cell Longev. 2012;2012:324832. PMID: 22701758.
7. Mulder GD, Patt LM, Sanders L, et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound Repair Regen. 1994;2(4):259-269. PMID: 1756155.
8. Pickart L, Margolina A. The effect of the human peptide GHK on gene expression relevant to nervous system function and cognitive decline. Brain Sci. 2017;7(2):20. PMID: 28212278.